Home          TPSA Story          Trustees & Helpers          Helplines          Contact Us          Forthcoming Events            Disclaimer

Newsletters          Become a Member          Become a Volunteer          Make a Donation

Symptoms     Diagnostic Test     Compare Treatments     Self Help Options     TPSA Buddies     Patients Experiences     Internet Resources      

About US







Torbay Prostate

Support Association

Copyright ©  TPSA  2015              Registered Charity Number  -  1095734

Serving men of all ages, and their partners, through a program of support before, during and after diagnosis.

New Topics

Sign our letters: Stand up for men caught in tug-of-war between NICE and Janssen.

Do you believe men should have access to cost-effective treatments that can give them more time with their loved ones, regardless of where they live, their age or other conditions they have?

Abiraterone is a hormone therapy that's currently extending the lives of men with late stage advanced prostate cancer. Anyone currently having abiraterone treatment will continue to receive it, but unless we change the course of an ongoing approval process, men with earlier stage disease may miss out on this life-extending treatment in future.

What happens if we do nothing?


Men in England, Wales and Northern Ireland who can't tolerate chemotherapy, because of their age or other conditions, may lose out on additional months of life. Worse still, this decision could set the tone for other similar treatments down the line, with many more men missing out on time with their loved ones. This is our last opportunity to influence this decision and we need you to send a message to NICE and Janssen.

Tony Collier (pictured above), has benefited from abiraterone for 4 years to manage his advanced prostate cancer. He says:


I know the difference abiraterone can make. I think this

rejection is absolutely shameful. I want as many people

as possible to sign up to Prostate Cancer UK’s campaign

asking them to reach an agreement that puts men first.

Tony Collier

Who can change this decision?


The National Institute for Health and Care Excellence (NICE) determines whether new and existing treatments and technologies provide cost-effective benefit for use on the NHS. Janssen make the hormone therapy, abiraterone. They cannot put their differences aside on the evidence required, and an affordable price. Men are caught in the middle of this tug-of-war. We’re extremely concerned that NICE is once again near to rejecting abiraterone as a first-line treatment that can give these men additional months of life. We urgently need both parties to put their differences aside and work together on the solutions that will give these men access to abiraterone.


What can I do?


Join us to urge key decision makers in both parties to work together for men across the UK, now and in future. Please sign our letters to NICE and Janssen to show you stand with men and their families.



We are pleased to announce a partnership between ourselves and Prostate Cancer Research

PCR are a charity funding research into treatments for Prostate Cancer patients. They fund a diverse portfolio of projects at some of the UK’s leading institutions in prostate cancer, ranging from early-stage biological insights to drug development.

Like us they are  keen to ensure men are seen as a whole person, and are working not only to add years to life; but  also adding life to years. Prostate cancer and the way it is currently treated brings physical and emotional side effects for the patient, their family and community, cuts too many lives short, and steals away the time that families should be able to spend together and enjoy. PCR, in partnership Tackle and with the pharmaceutical company Ipsen, are conducting a national patient survey; Talking Taboos

We know that one of the greatest issues prostate cancer patients face is talking effectively about their health, especially topics such as sexual function, incontinence, body issues and fatigue. The aim of the survey is to understand how many men find it hard to talk about these topics. Tackle, PCR and Ipsen will use the results to inform a national campaign that shows men that it’s okay to talk about their health, including the issues that are tough to talk about.

This is an important area and we would urge all men living with a diagnosis of prostate cancer to take part by completing the survey. To do this you’ll need to complete this (anonymous) survey. It should take no more than 15 minutes to complete and by sharing your views, you will be helping us to help other people affected by prostate cancer in the most effective way we can.

Please take part by clicking on the button below 


Earlier in 2021 Prostate Cancer Research (PCR), in partnership with Tackle Prostate Cancer and the pharmaceutical company Ipsen, launched a national survey to better understand the experiences faced by prostate cancer patients, especially related to the challenges concerning side effects.

We surveyed over 350 people with prostate cancer as part of this work. We have launched a new campaign, ‘Let’s Talk About the Hard Things’, spearheaded by Good Morning Britain’s Dr Hilary Jones, to break down the taboos surrounding the side effects of prostate cancer treatment and encourage people with prostate cancer to talk about their experiences with friends, family and healthcare professionals.

In our research we found that nearly 7 in 10 men feel that speaking to other men living with prostate cancer, or having their friends and family understand how they feel, would help them discuss some of the ‘hard’ topics more openly.


That is why we have launched a new series of powerful videos, featuring a diverse range of people affected by prostate cancer, each showcasing a different pairing discussing their experiences of prostate cancer and the side effects of their treatment. The videos, along with more detailed findings from our research, can be found at: www.pcr.org.uk/hard-things.

We hope these videos and this campaign helps members of your group and others open up with their healthcare professionals, their family, their friends and their peers.

‘Let’s Talk About the Hard Things’